Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: Methods and results from the NCI chemoprevention drug development program
- 1 January 1994
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 56 (S20), 32-54
- https://doi.org/10.1002/jcb.240560905
Abstract
In the NCI, Chemoprevention Branch drug development program, potential chemopreventive agents are evaluated for efficacy against chemical carcinogen–induced tumors in animal models. This paper summarizes the results of 144 agents in 352 tests using various animal efficacy models. Of these results, 146 were positive, representing 85 different agents. The target organs selected for the animals model are representative of high‐incidence human cancers. The assays include inhibition of tumors induced by MNU in hamster trachea, DEN in hamster lung, AOM in rat colon (including inhibition of AOM‐induced aberrant crypts), MAM in mouse colon, DMBA and MNU in rat mammary glands, DMBA promoted by TPA in mouse skin, and OH‐BBN in mouse bladder. The agents tested may be classified into various pharmacological and chemical structural categories that are relevant to their chemopreventive potential. These categories include antiestrogens, antiinflammatories (e. g., NSAIDs), antioxidants, arachidonic acid metabolism inhibitors, GST and GSH enhancers, ODC inhibitors, protein kinase C inhibitors, retinoids and carotenoids, organosulfur compounds, calcium compounds, vitamin D3 and analogs, and phenolic compounds (e. g., flavonoids). The various categories of compounds have different spectra of efficacy in animal models. In hamster lung, GSH‐enhancing agents and antioidants appear to have high potential for inhibiting carcinogenesis. In the colon, NSAIDs and other antiinflammatory agents appear particularly promising. Likewise, NSAIDs are very active in mouse bladder. In rat mammary glands, retinoids and antiestrogens (as would be expected) are efficacious. Several of the chemicals evaluated also appear to be promising chemopreventive agents based on their activity in several of the animal models. Particularly, the ODC inhibitor DFMO was active in the colon, mammary glands, and bladder models, while the dithiolthione, oltipraz, was efficacious in all the models listed above (i. e., lung, colon, mammary glands, skin, and bladder). 1994 Wiley‐Liss, Inc. 1 This article is a US Government work and, as such, is in the public domain in the United States of America.Keywords
This publication has 99 references indexed in Scilit:
- Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agentsCarcinogenesis: Integrative Cancer Research, 1994
- Dietary restriction reduces the incidence of NMU‐induced mammary tumors and alters retinoid tissue concentrations in ratsNutrition and Cancer, 1993
- Screening for chemopreventive (anticarcinogenic) compounds in rodentsMutation Research, 1992
- Hamster Lung Cancer Model of Carcinogenesis and ChemopreventionPublished by Springer Nature ,1992
- Review of the pharmacological properties of toremifeneJournal of Steroid Biochemistry, 1990
- Chemoprevention of experimental carcinogenesis in animalsPreventive Medicine, 1989
- Inhibition of dmba‐induced mammary tumorigenesis by caloric restriction in rats fed high‐fat dietsInternational Journal of Cancer, 1989
- Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: Preliminary findingsCancer Letters, 1987
- Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in ratsNature, 1985
- Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomataEuropean Journal of Cancer (1965), 1976